Marlin Global’s Q2 Gross Return Hits 2.0% Versus Benchmark’s 15.4% Surge

ICON’s Sharp Rebound Highlights Portfolio Strength

ICON’s 57% surge in the quarter was a standout for Marlin Global, following an accounting review that eased fears of financial restatements and showed no operational or cash flow disruption. The new CEO’s improved execution has accelerated bookings, supported by recovering biotech funding and pharma R&D spend, reinforcing confidence in ICON’s clinical research franchise. This rebound, with the stock climbing 160% from February lows, underscores how quickly sentiment can shift when fundamentals improve.

Semiconductors and Industrial Automation Drive Gains

Marlin’s semiconductor holdings contributed strongly, with ASML up 51%, Taiwan Semiconductor Manufacturing Co (TSMC) 42%, and Nvidia 15% in local currency terms. While the fund’s underweight to the broader semiconductor sector was a drag given the sector’s record 95% quarterly rise, the portfolio remains focused on durable AI enablers and platforms rather than speculative plays. Similarly, Keyence, a leader in industrial automation added earlier this year, rallied 48% as confidence grew in electronics and automotive market recoveries.

Healthcare Sector Faces Mixed Signals and Portfolio Adjustments

Healthcare holdings delivered a patchy performance. Zoetis, the global animal health leader, dropped 39% due to weaker consumer spending reducing vet visits and intensified competition in its dermatology segment. With new entrants driving deeper discounting and delayed pipeline launches until late 2027, Marlin has trimmed Zoetis to a below-average position. Boston Scientific also faced a 32% decline amid competitive pressures and hospital capacity constraints, although the company’s pipeline of minimally invasive devices offers longer-term growth potential.

Other medical device names like Intuitive Surgical (+14% procedure growth but -14% share price), Edwards Lifesciences (+13% revenue growth), and Dexcom (+7%) showed operational resilience despite market rotation into higher-momentum sectors. Marlin has been reducing overall healthcare exposure over the past year, concentrating on high-conviction companies with dominant market positions.

Market Environment: Narrow AI-Led Rally Amid Low Breadth

The US stock market posted its strongest quarter since 2020, with the S&P 500 up 15% and the Nasdaq surging 22%, driven by a narrow group of AI and semiconductor stocks. Less than 30% of companies outperformed the index, marking the lowest market breadth on record. High-quality companies underperformed cyclical peers by 16% in the quarter and over 70% in the last year, pushing valuations of quality growth stocks to their lowest since 2000. This dynamic presents a potential entry point for long-term investors focused on durable growth.

Memory stocks exemplify the risks of cyclical sectors. Despite AI-driven demand boosting prices and margins, Marlin remains cautious given the historical volatility and commoditised nature of memory products. Signs of demand moderation have emerged as large companies scale back AI spending and customers become more price sensitive.

Portfolio Performance and Dividend Update

Marlin Global’s gross performance return for Q2 was +2.0%, with an adjusted NAV return of +1.4%, both trailing the S&P Large Mid Cap/S&P Small Cap benchmark’s 15.4% rise. Total shareholder return over three years remains modestly positive at 2.6% annualised. The fund paid a 1.70 cents per share dividend on 26 June 2026, with 37% of shareholders participating in the dividend reinvestment plan at a 3% discount.

Senior Portfolio Manager Ashley Gardyne emphasised that despite the market’s fixation on near-term AI momentum, the underlying fundamentals of portfolio companies remain sound. The investment cycle is weighing on several names investing heavily in growth initiatives, including Meta, Tencent, Netflix, Intuitive Surgical, MercadoLibre, and Uber. Early signs of these investments paying off are emerging, such as Tencent’s AI revenue uplift and MercadoLibre’s logistics expansion.